During this stage, 300 articles were excluded due to irrelevance to the research question or failure to meet the inclusion criteria (22 clinical trials, 43 reviews or other unfitting literature, 112 wrong cell type, 49 wrong focus, 10 wrong drugs, 57 in vivo, 2 retractions, 3 no abstract and 2 not peer reviewed yet)
(2022) 107:e1339e47
The ideal candidate for Semaglutide in NYC includes: Adults with a BMI of 30 or higher (classified as obese) Individuals with a BMI of 27+ with weight-related health conditions such as high blood pressure, type 2 diabetes, or high cholesterol People struggling with portion control, food cravings, or emotional eating Patients looking for a doctor-supervised, non-surgical weight loss solution Anyone seeking long-term, sustainable weight loss without extreme dieting or excessive exercise Dr
Semaglutide can slow down the digestive process, which can cause complications during surgery
Several GLP-1 and dual GIP/GLP-1 receptor agonists have been developed to harness these pharmacological effects in the treatment of type 2 diabetes, with some demonstrating robust effectiveness in weight management and prevention of cardiovascular diseases